Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 851 to 875 of 1152 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
485 decreased catalytic activity (GO:0003824) nitric oxide synthase, endothelial (PR:000011328) 973: KE5 : Decrease, AKT/eNOS activity
486 decreased catalytic activity (GO:0003824) AKT kinase (PR:000029189) 973: KE5 : Decrease, AKT/eNOS activity
521 decreased catalytic activity (GO:0003824) type II iodothyronine deiodinase (PR:000006481) 1002: Inhibition, Deiodinase 2
526 decreased catalytic activity (GO:0003824) type I iodothyronine deiodinase (PR:000006480) 1009: Inhibition, Deiodinase 1
593 decreased catalytic activity (GO:0003824) Vitamin K Epoxide Reductases (MESH:D064417) 1134: Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone
603 decreased catalytic activity (GO:0003824) iodotyrosine deiodinase 1 (human) (PR:Q6PHW0) 1152: Inhibition, Iodotyrosine deiodinase (IYD)
604 decreased catalytic activity (GO:0003824) type III iodothyronine deiodinase (PR:000006482) 1153: Inhibition, Deiodinase 3
606 decreased catalytic activity (GO:0003824) dual oxidase 1 (PR:000006727) 1156: Inhibition, Dual oxidase
609 increased catalytic activity (GO:0003824) beta-1,3-glucuronyltransferase (PR:000001325) 295: Induction, Upregulation of glucuronyltransferase activity
257 decreased catalytic activity (GO:0003824) 17-beta-hydroxysteroid dehydrogenase 14 (PR:000008778) 482: Decreased, DHB4/HSD17B4
416 decreased catalytic activity (GO:0003824) iodotyrosine deiodinase 1 (mouse) (PR:Q9DCX8) 788: Decrease, Incorporation of active iodide into iodotyrosines
418 decreased catalytic activity (GO:0003824) 3-oxo-5-alpha-steroid 4-dehydrogenase 2 (rat) (PR:P31214) None
425 decreased catalytic activity (GO:0003824) Prolyl hydroxylases (MESH:D064828) 798: Inhibition, Prolyl hydroxylases
455 decreased catalytic activity (GO:0003824) uroporphyrinogen decarboxylase (PR:000017134) 845: Inhibition, UROD
495 abnormal cardiovascular system development (GO:0072358) cardiovascular system (UBERON:0004535) 317: Altered, Cardiovascular development/function
991 occurrence Cardiac arrest (HP:0001695) heart (UBERON:0000948) 1535: Heart failure
410 increased Carcinoma, Renal Cell (MESH:D002292) Adenoma (MESH:D000236) 713: Increase, Adenomas/carcinomas (renal tubular)
816 increased carboxypeptidase activity (GO:0004180) angiotensin-converting enzyme 2 (PR:000003622) 1854: Dysregulation, ACE2 expression and activity
582 decreased carboxylation reaction (MI:1139) prothrombin (PR:000007299) 1131: Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin)
583 decreased carboxylation reaction (MI:1139) coagulation factor VII (mouse) (PR:P70375) 1131: Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin)
584 decreased carboxylation reaction (MI:1139) coagulation factor IX (mouse) (PR:P16294) 1131: Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin)
585 decreased carboxylation reaction (MI:1139) coagulation factor X (mouse) (PR:O88947) 1131: Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin)
602 decreased carboxylation reaction (MI:1139) matrix Gla protein (mouse) (PR:P19788) 1169: Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment of post-translational modification (carboxylation) of osteocalcin
321 abnormal calmodulin binding (GO:0005516) calcium ion (CHEBI:39124) 1243: Altered, Ca2+-calmodulin activated signal transduction
116 decreased calcium-transporting ATPase activity (GO:0005388) calcium ion-transporting ATPase complex (GO:0090534) 51: Inhibition, Ca++ ATPase